114 related articles for article (PubMed ID: 12880986)
1. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.
Lange B; Schroeder U; Huebener N; Jikai J; Wenkel J; Strandsby A; Wrasidlo W; Gaedicke G; Lode HN
Cancer Lett; 2003 Jul; 197(1-2):225-30. PubMed ID: 12880986
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.
Jikai J; Shamis M; Huebener N; Schroeder U; Wrasidlo W; Wenkel J; Lange B; Gaedicke G; Shabat D; Lode HN
Cancer Lett; 2003 Jul; 197(1-2):219-24. PubMed ID: 12880985
[TBL] [Abstract][Full Text] [Related]
3. Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.
Schroeder U; Bernt KM; Lange B; Wenkel J; Jikai J; Shabat D; Amir R; Huebener N; Niethammer AG; Hagemeier C; Wiebusch L; Gaedicke G; Wrasidlo W; Reisfeld RA; Lode HN
Blood; 2003 Jul; 102(1):246-53. PubMed ID: 12623853
[TBL] [Abstract][Full Text] [Related]
4. In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.
Shabat D; Lode HN; Pertl U; Reisfeld RA; Rader C; Lerner RA; Barbas CF
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7528-33. PubMed ID: 11404472
[TBL] [Abstract][Full Text] [Related]
5. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Wickström M; Johnsen JI; Ponthan F; Segerström L; Sveinbjörnsson B; Lindskog M; Lövborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
Mol Cancer Ther; 2007 Sep; 6(9):2409-17. PubMed ID: 17876040
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells.
Wang D; Zhu Q; Zhang X; Zhang L; He Q; Yang B
Pharmazie; 2010 Jan; 65(1):51-6. PubMed ID: 20187579
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs.
Wrasidlo W; Schröder U; Bernt K; Hübener N; Shabat D; Gaedicke G; Lode H
Bioorg Med Chem Lett; 2002 Feb; 12(4):557-60. PubMed ID: 11844671
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility.
Niethammer A; Gaedicke G; Lode HN; Wrasidlo W
Bioconjug Chem; 2001; 12(3):414-20. PubMed ID: 11353540
[TBL] [Abstract][Full Text] [Related]
10. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
Yoon KJ; Qi J; Remack JS; Virga KG; Hatfield MJ; Potter PM; Lee RE; Danks MK
Mol Cancer Ther; 2006 Jun; 5(6):1577-84. PubMed ID: 16818517
[TBL] [Abstract][Full Text] [Related]
11. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
12. Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro.
Lowis SP; Newell DR; Pearson AD
Eur J Cancer; 1995; 31A(4):622-6. PubMed ID: 7576982
[TBL] [Abstract][Full Text] [Related]
13. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
14. Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma.
Colla R; Izzotti A; De Ciucis C; Fenoglio D; Ravera S; Speciale A; Ricciarelli R; Furfaro AL; Pulliero A; Passalacqua M; Traverso N; Pronzato MA; Domenicotti C; Marengo B
Oncotarget; 2016 Oct; 7(43):70715-70737. PubMed ID: 27683112
[TBL] [Abstract][Full Text] [Related]
15. Etoposide toxicity on human neuroblastoma cells in vitro is enhanced by preceeding hyperthermia.
Van Heek-Romanowski R; Pütter S; Trarbach T; Kremens B
Med Pediatr Oncol; 2001 Jan; 36(1):197-8. PubMed ID: 11464882
[TBL] [Abstract][Full Text] [Related]
16. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
17. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.
Meck MM; Wierdl M; Wagner LM; Burger RA; Guichard SM; Krull EJ; Harris LC; Potter PM; Danks MK
Cancer Res; 2001 Jul; 61(13):5083-9. PubMed ID: 11431345
[TBL] [Abstract][Full Text] [Related]
18. Real-time monitoring of etoposide prodrug activated by hydrogen peroxide with improved safety.
Zhu J; Chen J; Song D; Zhang W; Guo J; Cai G; Ren Y; Wan C; Kong L; Yu W
J Mater Chem B; 2019 Dec; 7(47):7548-7557. PubMed ID: 31720667
[TBL] [Abstract][Full Text] [Related]
19. N-myc amplification and its relationship to experimental therapy.
Livingstone A; Mairs RJ
J Neurooncol; 1997 Jan; 31(1-2):33-9. PubMed ID: 9049828
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.
Yavuz B; Zeki J; Coburn JM; Ikegaki N; Levitin D; Kaplan DL; Chiu B
J Control Release; 2018 Sep; 285():162-171. PubMed ID: 30018030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
